Get started
PARADIGM BIOPHARMACEUTICALS LIMITED..PARADIGM BIOPHARMACEUTICALS LIMITED..PARADIGM BIOPHARMACEUTICALS LIMITED..

PARADIGM BIOPHARMACEUTICALS LIMITED..

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

PAR trade ideas

Finer Market Points: ASX Top 10 Momentum Stocks: 31 Jan 2025TSX:ATH ASX:3DP NASDAQ:BXN NASDAQ:OPT ASX:ERM NYSE:PAR GETTEX:VTX LSE:GCM NYSE:EBR ASX:ESR Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list. The Launch Pad List is shared on Thursdays and the video interview published after market close on Fridays. Today's ASX's Top 10 Quarterly Momentum Stocks are: Alterity Therapeutics Limited (ATH) Pointerra Limited (3DP) Bioxyne Limited (BXN) Opthea Limited (OPT) Emmerson Resources Limited (ERM) Paradigm Biopharmaceuticals Limited (PAR) Vertex Minerals Limited (VTX) Green Critical Minerals Limited (GCM) EBR Systems, Inc. (EBR) Estrella Resources Limited (ESR)
ASX:PAR
by ch886
PARADIGM - 160% PROFIT TO CONTINUEPay close attention to PARADIGM (PAR). 3 Potential Moves 1. We bounce off the .382 Fib level and return to test the 2.80 mark which we saw on 11/05/20 -Being the end of the trading week I suspect the latter. 2. We break the .382 Fib level and Uptrend and head for the 'Golden Pocket' -Bounce off strong support at 2.00 mark -MACD is starting to squeeze but if we find momentum next week we could start to spread again. -PAR loves the .5 Fibonacci Retracement level. (Short term fact) -We hit the deeper uptrend and continue back up towards the 2.80 mark to test a strong EQ Resistance Level. Very Possible -It regains buyer momentum in the 'Golden Pocket' between the .5-.618 Fib Level. Very Possible -Positive news released early next week bring strong buying sentiment back into the market and create an Higher Low ready for the next leg up. 3. We BREAK both uptrend trendlines creating NEW Bearish Market Structure and head for the next Major Support @ 1.48 Another company im keeping a close eye on. PARADIGM BIOPHARMACEUTICALS LTD is a late stage drug development company with their aim to treat musculoskeletal disorders in humans with degenerative disease driven by injury, viral infection, aging or genetic predisposition. They have a cash balance sheet of $108 Million (06/04/20), FDA Approval, IP Protection & Patents, Agreements that stand for 20 years regarding manufacturing, Fully funded until 2022. EYES ON!!! These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
ASX:PAR
by Trader_Johnni
3
$PAR - PARADIGM BIOPHARMACEUTICALS - Steady riserPARADIGM BIOPHARMACEUTICALS (PAR:ASX) Has been trending nicely for a while now. More good news today with their next announcement "PARADIGM REPORTS CONSISTENT >50% PAIN REDUCTION IN KNEE OSTEOARTHRITIS PATIENTS" I like these kind of stocks in the medical space that are looking for alternative treatments to surgery. In the increasing world or obesity and ageing populations knee pain is massively increasing. How many people do you know of that have had some kind of knee surgery. Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury. I hold.
ASX:PARLong
by zAngus
11